中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
36期
50-51,52
,共3页
黄妙儿%刘鹏%观美华%黄云平%庞东燕%夏天%谭海葵
黃妙兒%劉鵬%觀美華%黃雲平%龐東燕%夏天%譚海葵
황묘인%류붕%관미화%황운평%방동연%하천%담해규
亚砷酸%反应停%维生素C%难治性复发性多发性骨髓瘤
亞砷痠%反應停%維生素C%難治性複髮性多髮性骨髓瘤
아신산%반응정%유생소C%난치성복발성다발성골수류
Arsenite%Thalidomide%Vitamin C%Refractory and relapsed multiple myeloma
目的：探讨亚砷酸联合反应停、维生素C治疗难治性复发性多发性骨髓瘤的临床疗效。方法：选取2003年3月-2013年4月本院收治的84例多发性骨髓瘤患者作为观察对象，随机分为治疗组43例和对照组41例，对照组采用常规疗法MP方案（马法兰+泼尼松），治疗组采用亚砷酸联合反应停、维生素C综合疗法，比较两组总有效率，并分别于治疗前后观察血象、骨髓象、肾功能、血清单克隆免疫球蛋白、血沉等指标，对比治疗前后各项指标的变化。结果：治疗组临床总有效率为83.7%，明显优于对照组的58.1%（P<0.05）；且治疗组血象、骨髓象、肾功能、血清单克隆免疫球蛋白、血沉等指标改善明显优于对照组（P<0.05）。结论：亚砷酸联合反应停、维生素C治疗难治性复发性多发性骨髓瘤患者疗效显著，能提高患者生活质量，值得临床推广应用。
目的：探討亞砷痠聯閤反應停、維生素C治療難治性複髮性多髮性骨髓瘤的臨床療效。方法：選取2003年3月-2013年4月本院收治的84例多髮性骨髓瘤患者作為觀察對象，隨機分為治療組43例和對照組41例，對照組採用常規療法MP方案（馬法蘭+潑尼鬆），治療組採用亞砷痠聯閤反應停、維生素C綜閤療法，比較兩組總有效率，併分彆于治療前後觀察血象、骨髓象、腎功能、血清單剋隆免疫毬蛋白、血沉等指標，對比治療前後各項指標的變化。結果：治療組臨床總有效率為83.7%，明顯優于對照組的58.1%（P<0.05）；且治療組血象、骨髓象、腎功能、血清單剋隆免疫毬蛋白、血沉等指標改善明顯優于對照組（P<0.05）。結論：亞砷痠聯閤反應停、維生素C治療難治性複髮性多髮性骨髓瘤患者療效顯著，能提高患者生活質量，值得臨床推廣應用。
목적：탐토아신산연합반응정、유생소C치료난치성복발성다발성골수류적림상료효。방법：선취2003년3월-2013년4월본원수치적84례다발성골수류환자작위관찰대상，수궤분위치료조43례화대조조41례，대조조채용상규요법MP방안（마법란+발니송），치료조채용아신산연합반응정、유생소C종합요법，비교량조총유효솔，병분별우치료전후관찰혈상、골수상、신공능、혈청단극륭면역구단백、혈침등지표，대비치료전후각항지표적변화。결과：치료조림상총유효솔위83.7%，명현우우대조조적58.1%（P<0.05）；차치료조혈상、골수상、신공능、혈청단극륭면역구단백、혈침등지표개선명현우우대조조（P<0.05）。결론：아신산연합반응정、유생소C치료난치성복발성다발성골수류환자료효현저，능제고환자생활질량，치득림상추엄응용。
Objective:To investigate the clinical efficacy of arsenious acid,vitamin C combined with thalidomide in treatment of relapsed and refractory multiple myeloma. Method:84 patients with multiple myeloma selected from March 2003 to April 2013 in our hospital were as study objects,and were randomly divided into treatment group 43 cases and control group 41 cases,control group with conventional therapy scheme MP (melphalan+prednisone),treatment group were treated with arsenic trioxide combined thalidomide,vitamin C synthesis therapy,compared the total efficiency of two groups,and were observed in blood,bone marrow,renal function,serum monoclonal immunoglobulin,erythrocyte sedimentation rate and other indicators before and after treatment,changes of various indexes were compared before and after the treatment. Result:The total effective rate in the treatment group was 83.7%,significantly better than the control group 58.1%(P<0.05);and the patients in the treatment group blood,bone marrow, renal function,serum monoclonal immunoglobulin,erythrocyte sedimentation rate and other indicators improved significantly better than the control group (P<0.05). Conclusion:Arsenic trioxide combined with thalidomide,vitamin C in the treatment of refractory and relapsed multiple myeloma patients with obvious curative effect,can improve the quality of life of patients,is worthy of clinical application.
